HD-OPM Archive
Topics › Weight, visceral & liver fat

Visceral fat drives residual CV risk through inflammation; GLP-1 agonists may help

Louis Nervegna · Aug 27, 2025 · ♥ 2 reactions · 0 comments · original Facebook post
Weight, visceral & liver fatInflammation & CRPGLP-1 drugs (semaglutide, tirzepatide)
AI summary & key facts

Louis shares a Frontiers in Cardiovascular Medicine review linking visceral adipose tissue to residual cardiovascular risk via chronic inflammation. It discusses GLP-1 receptor agonists as promising therapies.

#visceralfatHD #glp1HD #residualriskHD #inflammationHD

Research cited

Shared from Frontiers · original post

Visceral fat drives residual cardiovascular risk through chronic inflammation. This review explores the link and discusses GLP-1 agonists as promising treatments.

Read the article in Frontiers in Cardiovascular Medicine (Impact Factor 2.9, CiteScore 5.5) ⬇️

← newer: Harvard's Tobias: independently funded RCTs show red meat woolder: Certain probiotics may lower cholesterol and reduce inflamma →